Regenerative Patch Technologies

Jane Lebkowski, Ph.D., President 

Oct. 12 | 2:00pm | Oxford Biomedica Ballroom 

Menlo Park, CA 


In-person Presentation 

Regenerative Patch Technologies (RPT) is a biotechnology company focused on the development of cell-based implant technology for the treatment of retinal diseases. RPT has developed a composite subretinal implant, termed the California Project to Cure Blindness-Retinal Pigment Epithelium 1 (CPCB-RPE1), consisting of a polarized monolayer of human embryonic stem cell-derived RPE (hESC-RPE) on an ultrathin, synthetic parylene substrate designed to mimic Bruch’s membrane. The company has successfully filed an IND on the product and completed enrollment and three-year follow-up of subjects in a Phase I/IIa clinical trial with advanced dry age-related macular degeneration. RPT is actively planning for a Phase IIb clinical trial, the design of which has been cleared by FDA. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions